Investor FAQs

What is Bioblast's business focus?

Bioblast is a clinical-stage biotechnology company committed to developing clinically meaningful therapies for patients with rare and ultra-rare genetic diseases.

Given the interest in the scientific and medical community regarding alternative therapeutic uses of our lead drug candidate, trehalose 90mg/mL IV solution, Bioblast has decided to concentrate internal development efforts exclusively on trehalose.


Where can I find additional information about Bioblast?

Information can be accessed directly through the Company's web site (http://BioBlast-pharma.com). Annual 20-F reports, quarterly reports filed in a 6-K, and other filings with the SEC can be accessed directly through the Company web site or through the Securities and Exchange Commission at  http://www.sec.gov.


Where is Bioblast Pharma headquartered?

37 Dereh Menachem Begin St.
15th Floor, Tel-Aviv, Israel


What is Bioblast's stock symbol?

Bioblast common stock trades under the symbol “ORPN”.


Where does Bioblast's common stock trade?

Shares of Bioblast trade on the NASDAQ Global Market.


When did Bioblast complete its initial public offering (IPO) and what was the offering price?

Bioblast announced the pricing of its initial public offering of ordinary shares in July 2014 at an initial public offering price of $11.00 per share.


How many common share of Bioblast are outstanding?

The total number of shares outstanding for Bioblast is 16,391,770 .


When is the fiscal year-end for Bioblast?

Bioblast’s fiscal year-end is December 31st.


How do I invest in Bioblast?

Interested investors may purchase shares of Bioblast through any registered broker.


Does Bioblast offer a Direct Stock Purchase Plan?

No. Bioblast does not offer a Direct Stock Purchase Plan at this time.


Does Bioblast pay a dividend?

Bioblast does not currently pay a dividend to its stockholders.


Who is Bioblast's transfer agent and how does a registered shareholder contact the agent regarding account information?

VStock Transfer, LLC,
77 Spruce Street, Suite 201 Cedarhurst,
New York 11516
Facsimile: (646) 536-3179


Who is Bioblast's Independent auditor?

Bioblast’s independent auditor is Kost Forer Gabbay & Kasierer (a Member of Ernst & Young Global).


How do I contact Investor Relations?

For investor relations, please contact the following individuals:

LifeSci Advisors Contact
Matthew P. Duffy
Managing Director
212-915-0685
Matthew@LifeSciAdvisors.com

Bioblast Investor Relations Contact
ir@bioblastpharma.com